CSL Ltd. | Income Statement

Fiscal year is July-June. All values AUD Millions.
2014
2015
2016
2017
2018
Sales/Revenue
5,811
6,554
8,121
9,167
10,132
Cost of Goods Sold (COGS) incl. D&A
2,869
3,159
4,221
4,509
4,632
Gross Income
2,943
3,395
3,900
4,657
5,499
SG&A Expense
1,274
1,469
2,208
2,357
2,490
EBIT
1,669
1,926
1,693
-
3,009
Unusual Expense
70
26
-
-
-
Non Operating Income/Expense
185
185
525
45
63
Interest Expense
58
72
98
119
140
Pretax Income
1,748
2,058
2,138
2,241
2,944
Income Tax
324
402
431
467
713
Consolidated Net Income
1,424
1,656
1,707
1,773
2,231
Net Income
1,424
1,656
1,707
1,773
2,231
Net Income After Extraordinaries
1,424
1,656
1,707
1,773
2,231
Net Income Available to Common
1,424
1,656
1,707
1,773
2,231
EPS (Basic)
2.94
3.51
3.70
2.21
4.93
Basic Shares Outstanding
484
472
462
455
452
EPS (Diluted)
2.93
3.50
3.69
3.89
4.92
Diluted Shares Outstanding
486
473
463
456
454
EBITDA
1,881
2,144
1,995
2,671
3,392
Non-Operating Interest Income
22
19
19
14
12

About CSL

View Profile
Address
45 Poplar Road
Parkville Victoria (VIC) 3052
Australia
Employees -
Website http://www.csl.com.au
Updated 07/08/2019
CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma.